Global Pharmaceutical Drug Delivery

Pharmaceutical Drug Delivery Comprehensive Study by Type (Nano- and Micro-Particles, Transdermal Patches, Drug Reservoir Implants, Antibody-Drug Conjugates, Others), Application (Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Autoimmune Diseases, Others), Route of Administration (Buccal, Nasal, Oral, Transdermal, Others), End-User (Hospitals, Ambulatory Surgery Centre, Diagnostic Centre, Other) Players and Region - Global Market Outlook to 2030

Pharmaceutical Drug Delivery Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pharmaceutical Drug Delivery
A pharmaceutical drug delivery system (DDS) is a formulation or a device used to deliver a therapeutic substance into the body. This system works by delivering medications to specific parts of the body via a medium that can control therapy administration via a physiological or chemical trigger. DDS is used to improve the efficacy and safety of a drug by regulating the rate, time, and location of drug release in the body. Additionally, different routes of administration are used to introduce drug delivery systems into the body, such as oral drug delivery, pulmonary drug delivery, injectable drug delivery, nasal drug delivery, and others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The demand for Pharmaceutical Drug Delivery is increasing with each passing day. The businesses in this industry facing major competition with leading players of the market that includes Johnson & Johnson, Novartis International, Merck Group, Roche Holding AG and others. Many international as well as regional providers are also participants in the industry and directly compete with leaders. It has been identified that market leading players are investing heavily in growth strategies such as technological development, resource utilization to enhance their market position. The market leaders demonstrate a market-defining vision of how pharmaceutical drug delivery can help top-line business executives achieve their business objectives. Leaders have the ability to execute against that vision through both products and services. They have demonstrated solid business results in the form of revenue and earnings. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Pharmaceutical Drug Delivery market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Johnson & Johnson (United States), Novartis International (Switzerland), Merck Group (Germany), Roche Holding AG (Switzerland), Pfizer Inc. (United States), Bayer AG (Germany), Becton, Dickinson and Company (United States), GlaxoSmithKline (United Kingdom), 3M (United States), Sanofi (France), Genmab (Denmark), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Takeda (Japan), Amgen (United States), Bristol-Myers Squibb (United States), Gerresheimer AG (Germany) and Others are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Pharmaceutical Drug Delivery market by Type (Nano- and Micro-Particles, Transdermal Patches, Drug Reservoir Implants, Antibody-Drug Conjugates and Others), Application (Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Autoimmune Diseases and Others) and Region.



On the basis of geography, the market of Pharmaceutical Drug Delivery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Buccal will boost the Pharmaceutical Drug Delivery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Pharmaceutical Drug Delivery market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased demand for the various medicines like vitamin C, antivirals, during the COVID-19 pandemic spiked the demand for the pharmaceutical drug delivery

Market Growth Drivers:
Growing Prevalence of Chronic Diseases such as Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, and Neurological disorders and Surging Geriatric Population across the Globe

Challenges:
Rise in Number of Drug Recalls and Drug Failures Restricts the Growth of Pharmaceutical Drug Delivery Market and Increasing Cost of Healthcare Expenditure

Restraints:
Fluctuations in Raw Material Cost for Manufacturing Pharmaceutical Drug Delivery Devices

Opportunities:
Rising Investments in the Bio-Pharmaceutical Industry towards the Development of New Life-Saving Drugs

Market Leaders and their expansionary development strategies
In March 2022 Sandoz, a subsidiary of Novartis International had announced the acquisition of Coalesce. Sandoz has acquired Coalesce's strong expertise and assets, which will enable it to expand its existing respiratory medicine portfolio and improve patient access to these high-quality, complex products. Sandoz sees respiratory as a major pillar of its ambitious long-term growth strategy, with six in-market products and nearly twice as many in the pipeline. It plans to actively pursue more prospects both in-house and externally. Sandoz is also committed to expanding its complicated generics portfolio, which includes complex inflatables.



Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Pharmaceutical Drug Delivery Device Manufacturers, Government Regulatory Organizations, Corporate Entities and End-use industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Nano- and Micro-Particles
  • Transdermal Patches
  • Drug Reservoir Implants
  • Antibody-Drug Conjugates
  • Others
By Application
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Respiratory Diseases
  • Central Nervous System Disorders
  • Autoimmune Diseases
  • Others
By Route of Administration
  • Buccal
  • Nasal
  • Oral
  • Transdermal
  • Others

By End-User
  • Hospitals
  • Ambulatory Surgery Centre
  • Diagnostic Centre
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Chronic Diseases such as Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, and Neurological disorders
      • 3.2.2. Surging Geriatric Population across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Rise in Number of Drug Recalls and Drug Failures Restricts the Growth of Pharmaceutical Drug Delivery Market
      • 3.3.2. Increasing Cost of Healthcare Expenditure
    • 3.4. Market Trends
      • 3.4.1. Increased demand for the various medicines like vitamin C, antivirals, during the COVID-19 pandemic spiked the demand for the pharmaceutical drug delivery
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharmaceutical Drug Delivery, by Type, Application, Route of Administration, End-User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pharmaceutical Drug Delivery (Value)
      • 5.2.1. Global Pharmaceutical Drug Delivery by: Type (Value)
        • 5.2.1.1. Nano- and Micro-Particles
        • 5.2.1.2. Transdermal Patches
        • 5.2.1.3. Drug Reservoir Implants
        • 5.2.1.4. Antibody-Drug Conjugates
        • 5.2.1.5. Others
      • 5.2.2. Global Pharmaceutical Drug Delivery by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Cardiovascular Diseases
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Respiratory Diseases
        • 5.2.2.5. Central Nervous System Disorders
        • 5.2.2.6. Autoimmune Diseases
        • 5.2.2.7. Others
      • 5.2.3. Global Pharmaceutical Drug Delivery by: Route of Administration (Value)
        • 5.2.3.1. Buccal
        • 5.2.3.2. Nasal
        • 5.2.3.3. Oral
        • 5.2.3.4. Transdermal
        • 5.2.3.5. Others
      • 5.2.4. Global Pharmaceutical Drug Delivery by: End-User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Ambulatory Surgery Centre
        • 5.2.4.3. Diagnostic Centre
        • 5.2.4.4. Other
      • 5.2.5. Global Pharmaceutical Drug Delivery Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Pharmaceutical Drug Delivery (Price)
      • 5.3.1. Global Pharmaceutical Drug Delivery by: Type (Price)
  • 6. Pharmaceutical Drug Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck Group (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton, Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. 3M (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Genmab (Denmark)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Boehringer Ingelheim (Germany)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. AstraZeneca (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Takeda (Japan)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Amgen (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Bristol-Myers Squibb (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Gerresheimer AG (Germany)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Others
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
  • 7. Global Pharmaceutical Drug Delivery Sale, by Type, Application, Route of Administration, End-User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Pharmaceutical Drug Delivery (Value)
      • 7.2.1. Global Pharmaceutical Drug Delivery by: Type (Value)
        • 7.2.1.1. Nano- and Micro-Particles
        • 7.2.1.2. Transdermal Patches
        • 7.2.1.3. Drug Reservoir Implants
        • 7.2.1.4. Antibody-Drug Conjugates
        • 7.2.1.5. Others
      • 7.2.2. Global Pharmaceutical Drug Delivery by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Cardiovascular Diseases
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Respiratory Diseases
        • 7.2.2.5. Central Nervous System Disorders
        • 7.2.2.6. Autoimmune Diseases
        • 7.2.2.7. Others
      • 7.2.3. Global Pharmaceutical Drug Delivery by: Route of Administration (Value)
        • 7.2.3.1. Buccal
        • 7.2.3.2. Nasal
        • 7.2.3.3. Oral
        • 7.2.3.4. Transdermal
        • 7.2.3.5. Others
      • 7.2.4. Global Pharmaceutical Drug Delivery by: End-User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Ambulatory Surgery Centre
        • 7.2.4.3. Diagnostic Centre
        • 7.2.4.4. Other
      • 7.2.5. Global Pharmaceutical Drug Delivery Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Pharmaceutical Drug Delivery (Price)
      • 7.3.1. Global Pharmaceutical Drug Delivery by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pharmaceutical Drug Delivery: by Type(USD Million)
  • Table 2. Pharmaceutical Drug Delivery Nano- and Micro-Particles , by Region USD Million (2018-2023)
  • Table 3. Pharmaceutical Drug Delivery Transdermal Patches , by Region USD Million (2018-2023)
  • Table 4. Pharmaceutical Drug Delivery Drug Reservoir Implants , by Region USD Million (2018-2023)
  • Table 5. Pharmaceutical Drug Delivery Antibody-Drug Conjugates , by Region USD Million (2018-2023)
  • Table 6. Pharmaceutical Drug Delivery Others , by Region USD Million (2018-2023)
  • Table 7. Pharmaceutical Drug Delivery: by Application(USD Million)
  • Table 8. Pharmaceutical Drug Delivery Cancer , by Region USD Million (2018-2023)
  • Table 9. Pharmaceutical Drug Delivery Cardiovascular Diseases , by Region USD Million (2018-2023)
  • Table 10. Pharmaceutical Drug Delivery Diabetes , by Region USD Million (2018-2023)
  • Table 11. Pharmaceutical Drug Delivery Respiratory Diseases , by Region USD Million (2018-2023)
  • Table 12. Pharmaceutical Drug Delivery Central Nervous System Disorders , by Region USD Million (2018-2023)
  • Table 13. Pharmaceutical Drug Delivery Autoimmune Diseases , by Region USD Million (2018-2023)
  • Table 14. Pharmaceutical Drug Delivery Others , by Region USD Million (2018-2023)
  • Table 15. Pharmaceutical Drug Delivery: by Route of Administration(USD Million)
  • Table 16. Pharmaceutical Drug Delivery Buccal , by Region USD Million (2018-2023)
  • Table 17. Pharmaceutical Drug Delivery Nasal , by Region USD Million (2018-2023)
  • Table 18. Pharmaceutical Drug Delivery Oral , by Region USD Million (2018-2023)
  • Table 19. Pharmaceutical Drug Delivery Transdermal , by Region USD Million (2018-2023)
  • Table 20. Pharmaceutical Drug Delivery Others , by Region USD Million (2018-2023)
  • Table 21. Pharmaceutical Drug Delivery: by End-User(USD Million)
  • Table 22. Pharmaceutical Drug Delivery Hospitals , by Region USD Million (2018-2023)
  • Table 23. Pharmaceutical Drug Delivery Ambulatory Surgery Centre , by Region USD Million (2018-2023)
  • Table 24. Pharmaceutical Drug Delivery Diagnostic Centre , by Region USD Million (2018-2023)
  • Table 25. Pharmaceutical Drug Delivery Other , by Region USD Million (2018-2023)
  • Table 26. South America Pharmaceutical Drug Delivery, by Country USD Million (2018-2023)
  • Table 27. South America Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 28. South America Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 29. South America Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 30. South America Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 31. Brazil Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 32. Brazil Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 33. Brazil Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 34. Brazil Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 35. Argentina Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 36. Argentina Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 37. Argentina Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 38. Argentina Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 39. Rest of South America Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 40. Rest of South America Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 41. Rest of South America Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 42. Rest of South America Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 43. Asia Pacific Pharmaceutical Drug Delivery, by Country USD Million (2018-2023)
  • Table 44. Asia Pacific Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 45. Asia Pacific Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 47. Asia Pacific Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 48. China Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 49. China Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 50. China Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 51. China Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 52. Japan Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 53. Japan Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 54. Japan Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 55. Japan Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 56. India Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 57. India Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 58. India Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 59. India Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 60. South Korea Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 61. South Korea Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 62. South Korea Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 63. South Korea Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 64. Taiwan Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 65. Taiwan Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 66. Taiwan Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 67. Taiwan Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 68. Australia Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 69. Australia Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 70. Australia Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 71. Australia Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 76. Europe Pharmaceutical Drug Delivery, by Country USD Million (2018-2023)
  • Table 77. Europe Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 78. Europe Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 79. Europe Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 80. Europe Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 81. Germany Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 82. Germany Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 83. Germany Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 84. Germany Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 85. France Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 86. France Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 87. France Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 88. France Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 89. Italy Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 90. Italy Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 91. Italy Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 92. Italy Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 93. United Kingdom Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 94. United Kingdom Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 95. United Kingdom Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 96. United Kingdom Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 97. Netherlands Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 98. Netherlands Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 99. Netherlands Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 100. Netherlands Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 101. Rest of Europe Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 102. Rest of Europe Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 103. Rest of Europe Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 104. Rest of Europe Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 105. MEA Pharmaceutical Drug Delivery, by Country USD Million (2018-2023)
  • Table 106. MEA Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 107. MEA Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 108. MEA Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 109. MEA Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 110. Middle East Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 111. Middle East Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 112. Middle East Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 113. Middle East Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 114. Africa Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 115. Africa Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 116. Africa Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 117. Africa Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 118. North America Pharmaceutical Drug Delivery, by Country USD Million (2018-2023)
  • Table 119. North America Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 120. North America Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 121. North America Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 122. North America Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 123. United States Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 124. United States Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 125. United States Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 126. United States Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 127. Canada Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 128. Canada Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 129. Canada Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 130. Canada Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 131. Mexico Pharmaceutical Drug Delivery, by Type USD Million (2018-2023)
  • Table 132. Mexico Pharmaceutical Drug Delivery, by Application USD Million (2018-2023)
  • Table 133. Mexico Pharmaceutical Drug Delivery, by Route of Administration USD Million (2018-2023)
  • Table 134. Mexico Pharmaceutical Drug Delivery, by End-User USD Million (2018-2023)
  • Table 135. Pharmaceutical Drug Delivery: by Type(USD/Units)
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Pharmaceutical Drug Delivery: by Type(USD Million)
  • Table 155. Pharmaceutical Drug Delivery Nano- and Micro-Particles , by Region USD Million (2025-2030)
  • Table 156. Pharmaceutical Drug Delivery Transdermal Patches , by Region USD Million (2025-2030)
  • Table 157. Pharmaceutical Drug Delivery Drug Reservoir Implants , by Region USD Million (2025-2030)
  • Table 158. Pharmaceutical Drug Delivery Antibody-Drug Conjugates , by Region USD Million (2025-2030)
  • Table 159. Pharmaceutical Drug Delivery Others , by Region USD Million (2025-2030)
  • Table 160. Pharmaceutical Drug Delivery: by Application(USD Million)
  • Table 161. Pharmaceutical Drug Delivery Cancer , by Region USD Million (2025-2030)
  • Table 162. Pharmaceutical Drug Delivery Cardiovascular Diseases , by Region USD Million (2025-2030)
  • Table 163. Pharmaceutical Drug Delivery Diabetes , by Region USD Million (2025-2030)
  • Table 164. Pharmaceutical Drug Delivery Respiratory Diseases , by Region USD Million (2025-2030)
  • Table 165. Pharmaceutical Drug Delivery Central Nervous System Disorders , by Region USD Million (2025-2030)
  • Table 166. Pharmaceutical Drug Delivery Autoimmune Diseases , by Region USD Million (2025-2030)
  • Table 167. Pharmaceutical Drug Delivery Others , by Region USD Million (2025-2030)
  • Table 168. Pharmaceutical Drug Delivery: by Route of Administration(USD Million)
  • Table 169. Pharmaceutical Drug Delivery Buccal , by Region USD Million (2025-2030)
  • Table 170. Pharmaceutical Drug Delivery Nasal , by Region USD Million (2025-2030)
  • Table 171. Pharmaceutical Drug Delivery Oral , by Region USD Million (2025-2030)
  • Table 172. Pharmaceutical Drug Delivery Transdermal , by Region USD Million (2025-2030)
  • Table 173. Pharmaceutical Drug Delivery Others , by Region USD Million (2025-2030)
  • Table 174. Pharmaceutical Drug Delivery: by End-User(USD Million)
  • Table 175. Pharmaceutical Drug Delivery Hospitals , by Region USD Million (2025-2030)
  • Table 176. Pharmaceutical Drug Delivery Ambulatory Surgery Centre , by Region USD Million (2025-2030)
  • Table 177. Pharmaceutical Drug Delivery Diagnostic Centre , by Region USD Million (2025-2030)
  • Table 178. Pharmaceutical Drug Delivery Other , by Region USD Million (2025-2030)
  • Table 179. South America Pharmaceutical Drug Delivery, by Country USD Million (2025-2030)
  • Table 180. South America Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 181. South America Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 182. South America Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 183. South America Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 184. Brazil Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 185. Brazil Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 186. Brazil Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 187. Brazil Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 188. Argentina Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 189. Argentina Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 190. Argentina Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 191. Argentina Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 192. Rest of South America Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 193. Rest of South America Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 194. Rest of South America Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 195. Rest of South America Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 196. Asia Pacific Pharmaceutical Drug Delivery, by Country USD Million (2025-2030)
  • Table 197. Asia Pacific Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 198. Asia Pacific Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 199. Asia Pacific Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 200. Asia Pacific Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 201. China Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 202. China Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 203. China Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 204. China Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 205. Japan Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 206. Japan Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 207. Japan Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 208. Japan Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 209. India Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 210. India Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 211. India Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 212. India Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 213. South Korea Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 214. South Korea Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 215. South Korea Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 216. South Korea Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 217. Taiwan Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 218. Taiwan Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 219. Taiwan Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 220. Taiwan Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 221. Australia Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 222. Australia Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 223. Australia Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 224. Australia Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 225. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 226. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 227. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 228. Rest of Asia-Pacific Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 229. Europe Pharmaceutical Drug Delivery, by Country USD Million (2025-2030)
  • Table 230. Europe Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 231. Europe Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 232. Europe Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 233. Europe Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 234. Germany Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 235. Germany Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 236. Germany Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 237. Germany Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 238. France Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 239. France Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 240. France Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 241. France Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 242. Italy Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 243. Italy Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 244. Italy Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 245. Italy Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 246. United Kingdom Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 247. United Kingdom Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 248. United Kingdom Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 249. United Kingdom Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 250. Netherlands Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 251. Netherlands Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 252. Netherlands Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 253. Netherlands Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 254. Rest of Europe Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 255. Rest of Europe Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 256. Rest of Europe Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 257. Rest of Europe Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 258. MEA Pharmaceutical Drug Delivery, by Country USD Million (2025-2030)
  • Table 259. MEA Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 260. MEA Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 261. MEA Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 262. MEA Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 263. Middle East Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 264. Middle East Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 265. Middle East Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 266. Middle East Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 267. Africa Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 268. Africa Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 269. Africa Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 270. Africa Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 271. North America Pharmaceutical Drug Delivery, by Country USD Million (2025-2030)
  • Table 272. North America Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 273. North America Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 274. North America Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 275. North America Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 276. United States Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 277. United States Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 278. United States Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 279. United States Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 280. Canada Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 281. Canada Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 282. Canada Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 283. Canada Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 284. Mexico Pharmaceutical Drug Delivery, by Type USD Million (2025-2030)
  • Table 285. Mexico Pharmaceutical Drug Delivery, by Application USD Million (2025-2030)
  • Table 286. Mexico Pharmaceutical Drug Delivery, by Route of Administration USD Million (2025-2030)
  • Table 287. Mexico Pharmaceutical Drug Delivery, by End-User USD Million (2025-2030)
  • Table 288. Pharmaceutical Drug Delivery: by Type(USD/Units)
  • Table 289. Research Programs/Design for This Report
  • Table 290. Key Data Information from Secondary Sources
  • Table 291. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pharmaceutical Drug Delivery: by Type USD Million (2018-2023)
  • Figure 5. Global Pharmaceutical Drug Delivery: by Application USD Million (2018-2023)
  • Figure 6. Global Pharmaceutical Drug Delivery: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Pharmaceutical Drug Delivery: by End-User USD Million (2018-2023)
  • Figure 8. South America Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 9. Asia Pacific Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 10. Europe Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 11. MEA Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 12. North America Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 13. Global Pharmaceutical Drug Delivery: by Type USD/Units (2018-2023)
  • Figure 14. Global Pharmaceutical Drug Delivery share by Players 2023 (%)
  • Figure 15. Global Pharmaceutical Drug Delivery share by Players (Top 3) 2023(%)
  • Figure 16. Global Pharmaceutical Drug Delivery share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 20. Novartis International (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis International (Switzerland) Revenue: by Geography 2023
  • Figure 22. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Merck Group (Germany) Revenue: by Geography 2023
  • Figure 24. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 30. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Becton, Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 32. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 34. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 35. 3M (United States) Revenue: by Geography 2023
  • Figure 36. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 37. Sanofi (France) Revenue: by Geography 2023
  • Figure 38. Genmab (Denmark) Revenue, Net Income and Gross profit
  • Figure 39. Genmab (Denmark) Revenue: by Geography 2023
  • Figure 40. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 41. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 42. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 44. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 45. Takeda (Japan) Revenue: by Geography 2023
  • Figure 46. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 47. Amgen (United States) Revenue: by Geography 2023
  • Figure 48. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 49. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 50. Gerresheimer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 51. Gerresheimer AG (Germany) Revenue: by Geography 2023
  • Figure 52. Others Revenue, Net Income and Gross profit
  • Figure 53. Others Revenue: by Geography 2023
  • Figure 54. Global Pharmaceutical Drug Delivery: by Type USD Million (2025-2030)
  • Figure 55. Global Pharmaceutical Drug Delivery: by Application USD Million (2025-2030)
  • Figure 56. Global Pharmaceutical Drug Delivery: by Route of Administration USD Million (2025-2030)
  • Figure 57. Global Pharmaceutical Drug Delivery: by End-User USD Million (2025-2030)
  • Figure 58. South America Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 59. Asia Pacific Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 60. Europe Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 61. MEA Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 62. North America Pharmaceutical Drug Delivery Share (%), by Country
  • Figure 63. Global Pharmaceutical Drug Delivery: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (United States)
  • Novartis International (Switzerland)
  • Merck Group (Germany)
  • Roche Holding AG (Switzerland)
  • Pfizer Inc. (United States)
  • Bayer AG (Germany)
  • Becton, Dickinson and Company (United States)
  • GlaxoSmithKline (United Kingdom)
  • 3M (United States)
  • Sanofi (France)
  • Genmab (Denmark)
  • Boehringer Ingelheim (Germany)
  • AstraZeneca (United Kingdom)
  • Takeda (Japan)
  • Amgen (United States)
  • Bristol-Myers Squibb (United States)
  • Gerresheimer AG (Germany)
  • Others
Select User Access Type

Key Highlights of Report


Jan 2024 231 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pharmaceutical Drug Delivery Quantitative research analysis
Global Pharmaceutical Drug Delivery Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Johnson & Johnson (United States), Novartis International (Switzerland), Merck Group (Germany), Roche Holding AG (Switzerland), Pfizer Inc. (United States), Bayer AG (Germany), Becton, Dickinson and Company (United States), GlaxoSmithKline (United Kingdom), 3M (United States), Sanofi (France), Genmab (Denmark), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Takeda (Japan), Amgen (United States), Bristol-Myers Squibb (United States), Gerresheimer AG (Germany) and Others etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased demand for the various medicines like vitamin C, antivirals, during the COVID-19 pandemic spiked the demand for the pharmaceutical drug delivery" is seen as one of major influencing trends for Pharmaceutical Drug Delivery Market during projected period 2023-2030.
The Pharmaceutical Drug Delivery market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pharmaceutical Drug Delivery Report?

Have a Query? Click Here

Other Related Reports

Pruritus Drugs Comprehensive Study by Type (Antimicrobial, Cardiovascular,, Psychiatric/neurologic), Application (Cholestatic pruritus, Renal pruritus, Hematologic pruritus, Idiopathic generalize...
$ 3750
Solid Tumor Drugs Comprehensive Study by Type (Small Molecules, Biologics), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), Drug (Entrectinib, K...
$ 3750
Reishi Mushroom Supplements Comprehensive Study by End User Industries (Food & Beverage, Healthcare, Personal Care), Form (Liquid Extract, Powder Extract), Product (Organic Reishi Mushroom Extract, C...
$ 3450
Anti Ageing Ingredients Comprehensive Study by Type (Chemical Peels, Sunscreen Ingredients, Peptides, Hyaluronic Acid, Anti-Oxidants, Retinol, Niacinamide, Others), Application (Cosmetics, Food & Bev...
$ 3350
Heparin Injection Comprehensive Study by Type (1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, 20,000 USP/mL), Application (Thrombosis,, Pulmonary Embolism, Hemodialysis, Others), Heparin Type (Unfraction...
$ 3650
Opioid Use Disorder Comprehensive Study by Application (Moderate Pain Treatment, Severe Pain Treatment), Drug (Buprenorphine (Bunavail) Players and Region - Global Market Outlook to 2026
$ 3500